April 18, 2018 10:02 AM EDTUpdated May 26, 08:50 PM

Full FDA letter in hand, Solid Bio says it's working to reverse clinical hold on its DMD gene therapy

Amber Tong

Faced with skeptical investors and low share prices ever since the FDA slapped a clinical hold on its gene therapy for Duchenne muscular dystrophy, Solid …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Full FDA letter in hand, Solid Bio says it's working to reverse clinical hold on its DMD gene therapy

Amber Tong

Sign up to read this article for free.

Amgen’s once-a-month obesity shot shows 20% weight loss after a year

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Full FDA let­ter in hand, Sol­id Bio says it's work­ing to re­verse clin­i­cal hold on its DMD gene ther­a­py

Amber Tong

Sign up to read this article for free.

more like this

Am­gen’s once-a-month obe­si­ty shot shows 20% weight loss af­ter a year

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Full FDA letter in hand, Solid Bio says it's working to reverse clinical hold on its DMD gene therapy

Amgen’s once-a-month obesity shot shows 20% weight loss after a year

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role